Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Chao Gong

Hospitalist Dyer, IN Medical Doctor

NPI 1073836706 CMS profile 185236

24 Joliet St, Franciscan Hammond Clinic, Dyer, IN 46311

Open in the dashboard

General payments

$3,056

179 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Chao Gong of Dyer, IN is reported in the CMS Open Payments database as having received $3,056 across 179 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $497 28
2019 General $2,559 151

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chao Gong
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Chao Gong were reported at $0. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Chao Gong Hospitalist median Middle half National median
2019 $2,559 $96 $28–$201 $163
2020 $497 $48 $19–$125 $114
2021 $0 $70 $23–$167 $132
2022 $0 $85 $27–$174 $149
2023 $0 $89 $30–$191 $160
2024 $0 $95 $29–$204 $164
2025 $0 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Novartis Pharmaceuticals Corporation $480 28 payments
  2. Biogen, Inc. $370 26 payments
  3. Teva Pharmaceuticals USA, Inc. $361 20 payments
  4. Upsher-Smith Laboratories LLC $304 15 payments
  5. Lilly USA, LLC $196 11 payments
  6. UCB, Inc. $191 22 payments
  7. Aquestive Therapeutics, Inc. $183 6 payments
  8. Alexion Pharmaceuticals, Inc. $152 3 payments
  9. Amgen Inc. $123 7 payments
  10. Supernus Pharmaceuticals, Inc. $113 6 payments
  11. Other $583 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $3,056 179 payments
Products named General payments · program years 2019–2020
  1. AIMOVIG $527 29 payments
  2. TYSABRI $333 24 payments
  3. TECFIDERA $333 24 payments
  4. QUDEXY XR Topiramate Extended Release Capsules $304 15 payments
  5. AUSTEDO $222 13 payments
  6. Zembrace SymTouch Sumatriptan Injection $166 9 payments
  7. Soliris $152 3 payments
  8. AJOVY $139 7 payments
  9. SYMPAZAN $131 3 payments
  10. Tosymra Sumatriptan Nasal Spray $117 7 payments
  11. Other $1,229 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$72,680

Medicare's payments for the services billed

Medicare patients

370

Average age 75

Services billed

1,018

191 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 48%
Chronic kidney disease 46%
Diabetes 45%
Heart failure 42%
Depression 40%
Atrial fibrillation 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

179 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospitalist in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record